Molecule News and Research

RSS

New method for counting molecules

Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib, a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer.

18 Nov 2011

Dendrimers can capture circulating tumor cells in blood by biomimicry

The removal of rare tumor cells circulating in the blood might be possible with the use of biomolecules bound to dendrimers, highly branched synthetic polymers, which could efficiently sift and capture the diseased cells, according to new research at the University of Illinois at Chicago.

18 Nov 2011

First study to describe transporter system that bacteria use to ensure their survival

Bacteria responsible for middle ear infections, pink eye and sinusitis protect themselves from further immune attack by transporting molecules meant to destroy them away from their inner membrane target, according to a study from Nationwide Children's Hospital.

18 Nov 2011

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.

17 Nov 2011

Potential breakthrough in treating late-stage ovarian cancer

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often undetected disease.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011

Breakthrough in loading gold nanorods into cells could lead to new cancer treatment

Rice University chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell. The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

New research identifies brain chemicals and circuits involved in mental illnesses

New research identifies the brain chemicals and circuits involved in mental illnesses like schizophrenia, depression, and anxiety, giving potential new directions to their treatment.

16 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

New clues about connections among fat, inflammation and insulin resistance

In a new study, scientists report that they substantially curbed weight gain, improved metabolism, and improved the efficacy of insulin in mice by engineering them to express a specific human enzyme in their fat tissue. Although the obesity prevention came at the significant cost of widespread inflammation, the research offers new clues about the connections among obesity, insulin resistance and type 2 diabetes, and inflammation.

14 Nov 2011

Researchers get $7.5M grant to combat nerve agents

A $7.5 million award will help researchers harness the body’s own defenses to counteract nerve agents and create new types of antidotes for exposure to pesticides and other poisons.

14 Nov 2011

Sugary drinks raise risk of heart disease in women: Study

A new study shows that women who take sugared beverages every day may be raising their risk for heart disease, even if their habit is not packing on the pounds. The researchers say the drinks could be anything - sweet tea, soda, or coffee drinks that look like desserts.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease

Probiodrug AG, a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases, with a particular focus on Alzheimer's disease (AD), today announced top-line results of its Phase 1 single (SAD) and multiple ascending dose (MAD) study of PQ912 in healthy volunteers.

14 Nov 2011

Leonardo Biosystems receives second investment from Texas Emerging Technology Fund

Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

14 Nov 2011

Occupational chemical exposure raises for Parkinson's

A new research report contributes to the increasing evidence that repeated occupational exposure to certain chemical solvents raises the risk for Parkinson's disease. Researchers analyzed the occupational histories of twins in which one of the pair developed the neurodegenerative disorder, and assessed that twin's likelihood of exposure to six chemicals previously linked to Parkinson's.

14 Nov 2011

Molecule News and Research

New method for counting molecules

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Scientists identify novel gene mutation that causes glioblastoma

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Dendrimers can capture circulating tumor cells in blood by biomimicry

First study to describe transporter system that bacteria use to ensure their survival

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Potential breakthrough in treating late-stage ovarian cancer

New 2-DG-ABT combination cancer therapy triggers apoptosis

Breakthrough in loading gold nanorods into cells could lead to new cancer treatment

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

New research identifies brain chemicals and circuits involved in mental illnesses

Scientists determine atomic structure of Lassa fever viral protein

New clues about connections among fat, inflammation and insulin resistance

Researchers get $7.5M grant to combat nerve agents

Sugary drinks raise risk of heart disease in women: Study

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease

Leonardo Biosystems receives second investment from Texas Emerging Technology Fund

Occupational chemical exposure raises for Parkinson's

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News